The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia

Haematologica

Volumn 100, Issue 1, 2015, Pages 91-99

  Rajala, Hanna L M ^a   Olson, Thomas ^b   Clemente, Michael J ^c   Lagström, Sonja ^d   Ellonen, Pekka ^d   Lundan, Tuija ^e   Hamm, David E ^f   Arshi Uz Zaman, Syed ^d   Lopez Marti, Jesus M ^d   Andersson, Emma I ^a   Jerez, Andres ^c,g   Porkka, Kimmo ^a   Maciejewski, Jaroslaw P ^c   Loughran, Thomas P ^b   Mustjoki, Satu ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF VIRGINIA   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f Adaptive Biotechnologies Corp   (United States)

^g HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE; STAT3 PROTEIN; STAT5B PROTEIN; T LYMPHOCYTE RECEPTOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA EXTRACTION; FLOW CYTOMETRY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; MOLECULAR CLONING; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ASSAY; TREATMENT OUTCOME; ADULT; AGED; CANCER STAGING; CLONAL EVOLUTION; DRUG EFFECTS; FEMALE; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MALE; METABOLISM; MIDDLE AGED; MUTATION; NATURAL KILLER CELL; PATHOLOGY; PROCEDURES; PROGNOSIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CLONAL EVOLUTION; FEMALE; FOLLOW-UP STUDIES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84920156311     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.113142     Document Type: Article

References (39)

1. Loughran TP, Jr., Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102(2):169-75.
2. Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20(5):245-66.
3. Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95(9):1534-41.
4. Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood. 2008;111(3): 1610-6.
5. Hart DN, Baker BW, Inglis MJ, Nimmo JC, Starling GC, Deacon E, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood. 1992;79(8):2116-23.
6. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-62.
7. Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA. 2008;105 (42):16308-13.
8. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048-57.
9. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905-13.
10. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121(22):4541-50.
11. Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013;27 (7):1598-600.
12. Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA. STAT3 mutations are frequent in CD30+ T-cell lymphomas and Tcell large granular lymphocytic leukemia. Leukemia. 2013;27(11):2244-7.
13. Rajala HL, Porkka K, Maciejewski JP, Loughran TP Jr, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med. 2014;46(3):114-22.
14. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208(7):1359-66.
15. Couronne L, Scourzic L, Pilati C, Valle VD, Duffourd Y, Solary E, et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica. 2013;98(11):1748-52.
16. Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014;99(7):e105.
17. Hu G, Witzig TE, Gupta M. A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling. PloS One. 2013;8(7):e67851.
18. Kontro M, Kuusanmaki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(8):1738-42.
19. Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, Chen J, et al. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia. 2014;28(11):2244-8.
20. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, et al. Ultra-sensitive detection of rare T cell clones. J Immunol Methods. 2012;375(1-2):14-9.
21. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398-405.
22. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116(5):772-82.
23. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.
24. Kim MS, Lee SH, Yoo NJ, Lee SH. STAT3 exon 21 mutation is rare in common human cancers. Acta Oncol. 2013;52(6):1221-2.
25. Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, et al. STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122(14):2453-9.
26. Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity. 2011; 35(5):806-18.
27. Cui W, Liu Y, Weinstein JS, Craft J, Kaech SM. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity. 2011;35(5):792-805.
28. Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011;118(16):4384-93.
29. Andersson EI, Rajala HL, Eldfors S, Ellonen P, Olson T, Jerez A, et al. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J. 2013;3:e168.
30. Bedoya-Reina OC, Ratan A, Burhans R, Kim HL, Giardine B, Riemer C, et al. Galaxy tools to study genome diversity. Gigascience. 2013;2(1):17.
31. Teramo A, Gattazzo C, Passeri F, Lico A, Tasca G, Cabrelle A, et al. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood. 2013;121(19):3843-54.
32. Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk. 2012;12(6):400-5.
33. Lamy T, Loughran TP. Large granular lymphocyte leukemia. Cancer Control. 1998; 5(1):25-33.
34. Wlodarski MW, O'Keefe C, Howe EC, Risitano AM, Rodriguez A, Warshawsky I, et al. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood. 2005;106(8):2769-80.
35. Sandberg Y, Kallemeijn MJ, Dik WA, Tielemans D, Wolvers-Tettero IL, van Gastel-Mol EJ, et al. Lack of common TCRA and TCRB clonotypes in CD8(+)/TCRalphabeta(+) T-cell large granular lymphocyte leukemia: a review on the role of antigenic selection in the immunopathogenesis of CD8(+) T-LGL. Blood Cancer J. 2014;4:e172.
36. Clemente MJ, Przychodzen B, Jerez A, Dienes BE, Afable MG, Husseinzadeh H, et al. Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood. 2013;122(25):4077-85.
37. Bourcier KD, Lim DG, Ding YH, Smith KJ, Wucherpfennig K, Hafler DA. Conserved CDR3 regions in T-cell receptor (TCR) CD8(+) T cells that recognize the Tax11-19/HLA-A*0201 complex in a subject infected with human T-cell leukemia virus type 1: relationship of T-cell fine specificity and major histocompatibility complex/peptide/ TCR crystal structure. J Virol. 2001;75(20):9836-43.
38. Matsumoto I, Tsubota K, Satake Y, Kita Y, Matsumura R, Murata H, et al. Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjogren's syndrome. J Clin Invest. 1996;97(8):1969-77.
39. Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014;28(5):1134-6.